Skip to main content
SpringerLink
Log in

Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Many children with steroid-dependent nephrotic syndrome (NS) have significant sequelae despite steroid-sparing therapies. Levamisole may reduce short-term relapse frequency (RF) with minimal side effects. Little data exist, however, as to its long-term effect. To assess both short- and long-term efficacy in NS, RF and cumulative annual steroid burden were quantified in ten consecutive children with steroid-dependent NS treated with levamisole. Data were analyzed for three time periods: 1 year prior to levamisole therapy (Pre-Lev), during 1 year of levamisole therapy (During-Lev), and the year after cessation of all levamisole therapy (Off-Lev). Median RF fell from 6.0 (4.0–9.0) relapses/patient per year Pre-Lev to 0.0 (0.0–4.0) During-Lev (p = 0.002) with 6/10 patients having no relapse and 0.5 (0.0–8.0) Off-Lev (p = 0.01) with 5/10 patients without relapse. Concurrently, cumulative annual steroid burden fell from 6,067 (1,660–8,691) mg/m2 per year Pre-Lev to 2,920 (782–5,271) During-Lev (p = 0.002) and 716 (0–3,637) Off-Lev (p = 0.002). In 4/5 hypertensive children, blood pressure normalized During-Lev. Somatic indices also improved: height Z scores, which fell from 0.8 (−2.4 to 3.6) at diagnosis to −0.6 (−2.7 to 0.4) Pre-Lev (p = 0.004), remained stable at −0.6 (−3.0 to 0.6) after 1 year of therapy and –0.5 (−2.6 to 0.2) Off-Lev. Height velocity improved from 3.0 (0.3–6.0) cm/year Pre-Lev to 3.7 (0.0–8.0) cm/year During-Lev and 5.4 (0.0–9.1) Off-Lev. We conclude that levamisole is an effective short- and long-term steroid-sparing agent in pediatric NS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776

    CAS  Google Scholar 

  2. Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S (1980) Treatment of nephrotic syndrome with levamisole. J Pediatr 96:490–493

    Article  CAS  Google Scholar 

  3. British Association for Paediatric Nephrology (1991) Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. Lancet 337:1555–1557

    Article  Google Scholar 

  4. Niaudet P, Drachman R, Gagnadoux MF, Broyer M (1984) Treatment of idiopathic nephrotic syndrome with levamisole. Acta Paediatr Scand 73:637–641

    Article  CAS  Google Scholar 

  5. Al-Saran K, Mirza K, Al-Ghanam G, Abdelkarim M (2006) Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome. Pediatr Nephrol 21:201–205

    Article  CAS  Google Scholar 

  6. Dayal U, Dayal AK, Shastry JC, Raghupathy P (1994) Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children. Nephron 66:408–412

    Article  CAS  Google Scholar 

  7. Donia AF, Amer GM, Ahmed HA, Gazareen SH, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA (2002) Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children. Pediatr Nephrol 17:355–358

    Article  Google Scholar 

  8. Alsaran K, Grisaru S, Stephens D, Arbus G (2001) Levamisole vs. cyclophosphamide for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 56:289–294

    CAS  PubMed  Google Scholar 

  9. Sumegi V, Haszon I, Ivanyi B, Bereczki C, Papp F, Turi S (2004) Long-term effects of levamisole treatment in childhood nephrotic syndrome. Pediatr Nephrol 19:1354–1360

    Article  Google Scholar 

  10. Durkan AM, Hodson EM, Willis NS, Craig JC (2001) Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials. Kidney Int 59:1919–1927

    Article  CAS  Google Scholar 

  11. Bagga A, Sharma A, Srivastava RN (1997) Levamisole therapy in corticosteroid-dependent nephrotic syndrome. Pediatr Nephrol 11:415–417

    Article  CAS  Google Scholar 

  12. Donatti TL, Koch VH, Fujimura MD, Okay Y (2003) Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients. Pediatr Nephrol 18:789–795

    Article  Google Scholar 

  13. Emma F, Sesto A, Rizzoni G (2003) Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol 18:783–788

    Article  Google Scholar 

  14. Chesney RW, Mazess RB, Rose P, Jax DK (1978) Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child 132:768–772

    CAS  PubMed  Google Scholar 

  15. Blodgett FM, Burgin L, Iezzoni D, Gribetz D, Talbot NB (1956) Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children. N Engl J Med 254:636–641

    Article  CAS  Google Scholar 

  16. Fleisher DS, Mc CW, Rapoport M (1960) The effects of intermittent doses of adrenocortical steroids on the statural growth of nephrotic children. J Pediatr 57:192–198

    Article  CAS  Google Scholar 

  17. Padilla R, Brem AS (1989) Linear growth of children with nephrotic syndrome: effect of alkylating agents. Pediatrics 84:495–499

    CAS  PubMed  Google Scholar 

  18. Barbano G, Ginevri F, Ghiggeri GM, Gusmano R (1999) Disseminated autoimmune disease during levamisole treatment of nephrotic syndrome. Pediatr Nephrol 13:602–603

    Article  CAS  Google Scholar 

  19. Rongioletti F, Ghio L, Ginevri F, Bleidl D, Rinaldi S, Edefonti A, Gambini C, Rizzoni G, Rebora A (1999) Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol 140:948–951

    Article  CAS  Google Scholar 

  20. Palcoux JB, Niaudet P, Goumy P (1994) Side effects of levamisole in children with nephrosis. Pediatr Nephrol 8:263–264

    Article  CAS  Google Scholar 

  21. Dubey AK, Gupta RK, Sharma RK (2001) Levamisole induced ataxia. Indian Pediatr 38:417–419

    CAS  PubMed  Google Scholar 

  22. Bulugahapitiya DT (1997) Liver toxicity in a nephrotic patient treated with levamisole. Arch Dis Child 76:289

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Children’s Hospital Boston, 300 Longwood Avenue, Boston, MA, 02115, USA

    Olivia Boyer, Janelle K. Moulder & Michael J. G. Somers

  2. Biostatistics and Medical Information Service, Necker Hospital, Paris, France

    Laure Grandin

Authors
  1. Olivia Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janelle K. Moulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laure Grandin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael J. G. Somers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. G. Somers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boyer, O., Moulder, J.K., Grandin, L. et al. Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr Nephrol 23, 575–580 (2008). https://doi.org/10.1007/s00467-007-0708-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-007-0708-7

Keywords

Search

Navigation